mln-8237 and Lymphoproliferative-Disorders

mln-8237 has been researched along with Lymphoproliferative-Disorders* in 1 studies

Trials

1 trial(s) available for mln-8237 and Lymphoproliferative-Disorders

ArticleYear
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:2

    Alisertib, an Aurora kinase A inhibitor, was evaluated in a Phase 1 study in combination with the histone deacetylase inhibitor vorinostat, in patients with relapsed/refractory lymphoid malignancies (

    Topics: Aurora Kinase A; Azepines; Histone Deacetylase Inhibitors; Humans; Lymphoproliferative Disorders; Neoplasm Recurrence, Local; Pyrimidines; Vorinostat

2020